UID:
almafu_9959328781102883
Umfang:
1 online resource :
,
illustrations
ISBN:
9783527655946
,
3527655948
,
9783527655977
,
3527655972
,
9781299178762
,
1299178766
Anmerkung:
Machine generated contents note: 1. Lipidomics Perspective: From Molecular Lipidomics to Validated Clinical Diagnostics / Kim Ekroos -- 1.1. Introduction -- 1.2. Hierarchical Categorization of the Analytical Lipid Outputs -- 1.2.1. Lipid Class -- 1.2.2. Sum Compositions -- 1.2.3. Molecular Lipids -- 1.2.4. Structurally Defined Molecular Lipids -- 1.3. The Type of Lipid Information Delivers Different Biological Knowledge -- 1.4. Untying New Biological Evidences through Molecular Lipidomic Applications -- 1.5. Molecular Lipidomics Approaches Clinical Diagnostics -- 1.6. Current Roadblocks in Lipidomics -- 1.7. Conclusions -- References -- 2. Lipids in Cells / Michal Surma -- 2.1. Introduction -- 2.2. Basis of Cellular Lipid Distribution -- 2.3. Lipid Distribution by Nonvesicular Routes -- 2.4. Lipids in Different Cell Types -- 2.5. Functional Implications of Membrane Lipid Composition -- 2.6. Outlook: Collectives and Phase Separation -- References -- 3. High-Throughput Molecular Lipidomics / Kim Ekroos -- 3.1. Introduction -- 3.2. Lipid Diversity -- 3.3. Function of Molecular Lipids -- 3.4. Automated Sample Preparation -- 3.5. Different Approaches to Molecular Lipidomics -- 3.5.1. Untargeted versus Targeted Approaches -- 3.5.2. Shotgun Lipidomics -- 3.5.3. Analytical Validation of the Shotgun Approach -- 3.5.4. Targeted LC-MS Lipidomics -- 3.6. Data Processing and Evaluation -- 3.7. Lipidomic Workflows -- 3.8. Conclusions and Future Perspectives -- References -- 4. Multidimensional Mass Spectrometry-Based Shotgun Lipidomics / Xianlin Han -- 4.1. Introduction -- 4.2. Multidimensional Mass Spectrometry-Based Shotgun Lipidomics -- 4.2.1. Intrasource Separation -- 4.2.2. The Principle of Multidimensional Mass Spectrometry -- 4.2.3. Variables in Multidimensional Mass Spectrometry -- 4.2.3.1. Variables in Fragment Monitoring by Tandem MS Scans -- 4.2.3.2. Variables Related to the Infusion Conditions -- 4.2.3.3. Variables under Ionization Conditions -- 4.2.3.4. Variables under Collision Conditions -- 4.2.3.5. Variables Related to the Sample Preparations -- 4.3. Application of Multidimensional Mass Spectrometry-Based Shotgun Lipidomics for Lipidomic Analysis -- 4.3.1. Identification of Lipid Molecular Species by 2D Mass Spectrometry -- 4.3.1.1. Identification of Anionic Lipids -- 4.3.1.2. Identification of Weakly Anionic Lipids -- 4.3.1.3. Identification of Charge Neutral but Polar Lipids -- 4.3.1.4. Identification of Sphingolipids -- 4.3.1.5. The Concerns of the MDMS-Based Shotgun Lipidomics for Identification of Lipid Species -- 4.3.2. Quantification of Lipid Molecular Species by MDMS-Based Shotgun Lipidomics -- 4.3.2.1. The Principle of Quantification of Individual Lipid Species by MS -- 4.3.2.2. Quantification by Using a Two-Step Procedure in MDMS-Based Shotgun Lipidomics -- 4.3.2.3. Quantitative Analysis of PEX7 Mouse Brain Lipidome by MDMS-Based Shotgun Lipidomics -- 4.4. Conclusions -- References -- 5. Targeted Lipidomics: Sphingolipidomics / M. Cameron Sullards -- 5.1. Introduction -- 5.2. Sphingolipids Description and Nomenclature -- 5.3. Sphingolipids Analysis via Targeted LC-MS/MS -- 5.3.1. Sphingolipid Internal Standards -- 5.3.2. Biological Sample Preparation and Storage -- 5.3.3. Sphingolipid Extraction Protocol -- 5.3.4. Liquid Chromatography -- 5.3.4.1. LCBs and Cer1P -- 5.3.4.2. Cer, HexCer, LacCer, SM, ST, and Cer1P -- 5.3.4.3. Separation of GlcCer and GalCer -- 5.3.5. Mass Spectrometry -- 5.3.5.1. Electrospray Ionization -- 5.3.5.2. Tandem Mass Spectrometry -- 5.3.5.3. Multiple Reaction Monitoring -- 5.3.6. Generation of Standard Curves -- 5.3.7. Data Analysis -- 5.3.8. Quality Control -- 5.4. Applications of Sphingolipidomics in Biology and Disease -- 5.4.1. LC-MS/MS -- 5.4.2. Transcriptomic Guided Tissue Imaging Mass Spectrometry -- 5.5. Conclusions -- References -- 6. Structural Lipidomics / Stephen J. Blanksby -- 6.1. Introduction -- 6.2. Lipid Structure -- 6.3. Structural Analysis of Lipids by Mass Spectrometry -- 6.4.sn Position -- 6.5. Double Bond Position -- 6.5.1. Untargeted Fragmentation -- 6.5.2. Targeted Fragmentation -- 6.6. Double Bond Stereochemistry -- 6.7. Conclusions -- References -- 7. Imaging Lipids in Tissues by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry / Robert C. Murphy -- 7.1. Introduction -- 7.2. Sample Preparation -- 7.3. Matrix -- 7.3.1. Techniques for Matrix Application -- 7.3.2. Matrix Compounds -- 7.4. Instrumentation -- 7.4.1. Lasers and Rastering -- 7.4.2. Ion Formation -- 7.4.3. Mass Analyzers and Ion Detection -- 7.5. Data Processing -- 7.6. Conclusions -- References -- 8. Lipid Informatics: From a Mass Spectrum to Interactomics / Kirill Tarasov -- 8.1. Introduction -- 8.2. Lipid Nomenclature -- 8.3. Basic Properties of Lipid Mass spectrometric Data -- 8.3.1. Mass Spectrum -- 8.3.2. Mass Accuracy and Reproducibility -- 8.3.3. Isotopes, Deisotoping, and Isotope Correction -- 8.4. Data Processing -- 8.4.1. De Novo Lipid Identification -- 8.4.2. Targeted Export of Lipidomic Data -- 8.4.3. Normalization of lipidomic Data -- 8.5. Lipidomic Data Mining and Visualization -- 8.5.1.Comparative Lipidomics -- 8.5.2. Multivariate Data Analysis -- 8.5.3. Lipidomics in Biomarker Research -- 8.6. Lipidomic Data Integration -- 8.7. Conclusions and Future Perspectives -- References -- 9. Lipids in Human Diseases / Scott A.
,
Summers -- 9.1. Introduction -- 9.2. Obesity -- 9.3. Dyslipidemia -- 9.4. Diabetes -- 9.5. Cardiovascular Disorders -- 9.6. Hereditary Sensory Neuropathy -- 9.7. Neurodegeneration -- 9.8. Cancer -- 9.9. Lysosomal Storage Disorders -- 9.10. Cystic Fibrosis -- 9.11. Anti-Inflammatory Lipid Mediators -- 9.12. Conclusions -- References -- 10. Lipidomics in Lipoprotein Biology / Anatol Kontush -- 10.1. Introduction -- 10.2. Metabolism of Lipoproteins -- 10.3. Lipoproteinomics in Normolipidemic Subjects -- 10.3.1. Phospholipids -- 10.3.1.1. Phosphatidylcholine -- 10.3.1.2. Lysophosphatidylcholine -- 10.3.1.3. Phosphatidylethanolamine -- 10.3.1.4. Phosphatidylethanolamine Plasmalogens -- 10.3.1.5. Phosphatidylinositol, Phosphatidylserine, Phosphatidylglycerol, and Phosphatidic Acid -- 10.3.1.6. Cardiolipin -- 10.3.1.7. Isoprostane-Containing PC -- 10.3.2. Sphingolipids -- 10.3.2.1. Sphingomyelin -- 10.3.2.2. Lysosphingolipids -- 10.3.2.3. Ceramide -- 10.3.2.4. Minor Sphingolipids -- 10.3.3. Sterols -- 10.3.4. Cholesteryl Esters -- 10.3.5. Triacylglycerides -- 10.3.6. Minor Lipids -- 10.4. Altered Lipoproteinomics in Dyslipidemia -- 10.4.1. Phospholipids -- 10.4.1.1. Phosphatidylcholine -- 10.4.1.2. Lysophosphatidylcholine -- 10.4.1.3. Phosphatidylethanolamine -- 10.4.1.4. Phosphatidylethanolamine Plasmalogens -- 10.4.1.5. Phosphatidylinositol -- 10.4.1.6. Isoprostane-Containing PC -- 10.4.2. Sphingolipids -- 10.4.2.1. Sphingomyelin -- 10.4.2.2. Lysosphingolipids: S1P and Dihydro S1P -- 10.4.2.3. Ceramide -- 10.4.3. Free Cholesterol -- 10.4.4. Cholesteryl Esters -- 10.4.5. Triacylglycerides -- 10.4.6. Minor Lipids -- 10.4.6.1. Nonesterified Fatty Acids -- 10.4.6.2. Ganglioside GM1 -- 10.4.6.3. Oxidized Lipids -- 10.5. Conclusions -- References -- 11. Mediator Lipidomics in Inflammation Research / Yosuke Isobe -- 11.1. Introduction -- 11.2. PUFA-Derived Lipid Mediators: Formation and Action -- 11.3. LC-ESI-MS/MS-Based Lipidomics -- 11.3.1. Sample Preparation -- 11.3.2. LC-ESI-MS/MS Analysis -- 11.4. Mediator Lipidomics in Inflammation and Resolution -- 11.5. Conclusion and Future Perspective -- References -- 12. Lipidomics for Elucidation of Metabolic Syndrome and Related Lipid Metabolic Disorder / Hiroki Nakanishi -- 12.1. Introduction -- 12.2. Basic Strategy of Lipidomics for Elucidating Metabolic Changes of Lipids at the Level of their Molecular Species in Metabolic Syndrome and Related Diseases -- 12.3. Analytical Systems by Mass Spectrometry in Lipidomics -- 12.3.1. LC-MS and LC-MS/MS Analyses for Global Detection of Phospholipids and Triglycerides -- 12.3.2. Infusion Analysis with Precursor Ion and Neutral Loss Scanning -- 12.3.3. Targeted Analysis by Multiple Reaction Monitoring for Oxidized Lipids and Lipid Mediators by LC-MS/MS on Triple-Stage Quadrupole Mass Spectrometers -- 12.4. Lipidomic Data Processing -- 12.4.1. Strategy of Lipid Search -- 12.4.2. Application and Identification Results of "Lipid Search" -- 12.5. Analysis of Lipids as Markers of Metabolic Syndrome -- 12.5.1. Oxidized Phospholipids -- 12.5.1.1. Application for Myocardial Ischemia-Reperfusion Model -- 12.5.2. Bioactive Acidic Phospholipids -- 12.5.2.1. Lysophosphatidic Acid -- 12.5.2.2. Phosphoinositides -- 12.5.3. Oxidative Triglycerides -- 12.5.3.1. Application for Mouse White Adipose Tissue -- 12.5.4. Sphingolipids -- 12.5.4.1. Application for Sphinogolipid Metabolism -- 12.6. Direct Detection of Lipid Molecular Species in Specific Tissue Domains by Disease-Specific Changes -- 12.7. Conclusions -- References -- 13. Lipidomics in Atherosclerotic Vascular Disease / Reijo Laaksonen -- 13.1. Introduction -- 13.2. Lipids and Atherosclerotic Vascular Disease -- 13.2.1. Lipoproteins -- 13.2.2. Atherosclerotic Plaque -- 13.2.3. Molecular Lipids -- 13.2.3.1. Eicosanoids -- 13.2.3.2. Sphingolipids and Cholesterol -- 13.2.3.3. Phospholipids -- 13.2.4. Animal Models of Atherosclerotic Research -- 13.3. Diagnostics and Treatment -- 13.3.1. Diagnostic Biomarkers of Atherosclerosis -- 13.3.2. Lipidomics in Efficacy and Safety Measurements -- 13.4. Conclusions -- References -- 14. Lipid Metabolism in Neurodegenerative Diseases / Markus R. Wenk -- 14.1. Introduction -- 14.1.1. Brain Lipids -- 14.1.2. Mass Spectrometry of Brain Lipids -- 14.2. Alzheimer's Disease -- 14.2.1. Cholesterol and Cholesterol Esters -- 14.2.2. Sulfatides -- 14.2.3. Plasmalogen Ethanolamines -- 14.2.4. Phospholipases -- 14.2.4.1. Phospholipase A2 -- 14.2.4.2. Phospholipase C and Phospholipase D -- 14.3. Parkinson's Disease -- 14.3.1. Cerebrosides -- 14.3.2. Coenzyme Q -- 14.3.3. Endocannabinoids -- 14.4. Conclusions -- References -- 15. The Tumor Mitochondrial Lipidome and Respiratory Bioenergetic Insufficiency / Michael A. Kiebish -- 15.1. Introduction -- 15.1.1. Lipidomic Abnormalities in Tumor Mitochondria.
Weitere Ausg.:
Print version: Lipidomics. Weinheim : Wiley-VCH, ©2012 ISBN 9783527330980
Sprache:
Englisch
Fachgebiete:
Chemie/Pharmazie
,
Biologie
,
Medizin
Schlagwort(e):
Electronic books.
;
Aufsatzsammlung
;
Electronic books.
;
Electronic books.
DOI:
10.1002/9783527655946
URL:
https://onlinelibrary.wiley.com/doi/book/10.1002/9783527655946
URL:
https://onlinelibrary.wiley.com/doi/book/10.1002/9783527655946
URL:
https://onlinelibrary.wiley.com/doi/book/10.1002/9783527655946
Bookmarklink
